Ironwood Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Ironwood Pharmaceuticals' es Tom McCourt , nombrado en Mar 2021, tiene una permanencia de 3.08 años. compensación anual total es $7.89M, compuesta por 10.2% salario y 89.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.37% de las acciones de la empresa, por valor de $4.67M. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 5 años, respectivamente.
Información clave
Tom McCourt
Chief Executive Officer (CEO)
US$7.6m
Compensación total
| Porcentaje del salario del CEO | 11.0% |
| Permanencia del CEO | 3.2yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 2.7yrs |
| Promedio de permanencia en la Junta Directiva | 5.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16
Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Ironwood Pharmaceuticals: Undervalued Company With Steady Growth
Sep 27Here's Why I Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Might Deserve Your Attention Today
Jul 21Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Jun 22Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$8m | US$834k | -US$1b |
| Sep 30 2023 | n/a | n/a | -US$952m |
| Jun 30 2023 | n/a | n/a | -US$917m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$8m | US$805k | US$175m |
| Sep 30 2022 | n/a | n/a | US$168m |
| Jun 30 2022 | n/a | n/a | US$173m |
| Mar 31 2022 | n/a | n/a | US$527m |
| Dec 31 2021 | US$9m | US$732k | US$528m |
| Sep 30 2021 | n/a | n/a | US$530m |
| Jun 30 2021 | n/a | n/a | US$509m |
| Mar 31 2021 | n/a | n/a | US$143m |
| Dec 31 2020 | US$3m | US$576k | US$106m |
| Sep 30 2020 | n/a | n/a | US$111m |
| Jun 30 2020 | n/a | n/a | US$97m |
| Mar 31 2020 | n/a | n/a | US$84m |
| Dec 31 2019 | US$5m | US$511k | US$59m |
| Sep 30 2019 | n/a | n/a | US$19m |
| Jun 30 2019 | n/a | n/a | -US$153m |
| Mar 31 2019 | n/a | n/a | -US$173m |
| Dec 31 2018 | US$2m | US$465k | -US$194m |
| Sep 30 2018 | n/a | n/a | -US$190m |
| Jun 30 2018 | n/a | n/a | -US$71m |
| Mar 31 2018 | n/a | n/a | -US$108m |
| Dec 31 2017 | US$2m | US$450k | -US$55m |
Compensación vs. Mercado: La compensación total de Tom($USD7.89M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Tom ha sido consistente con los resultados de la empresa en el último año.
CEO
Tom McCourt (66 yo)
3.2yrs
Permanencia
US$7,583,270
Compensación
Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 3.2yrs | US$7.58m | 0.36% $ 4.5m | |
| Senior VP | 2.4yrs | US$2.76m | 0.11% $ 1.4m | |
| Senior VP | 2.8yrs | US$2.44m | 0.085% $ 1.0m | |
| Chief Medical Officer | 5.3yrs | US$2.60m | 0.17% $ 2.1m | |
| Senior VP & Chief Business Officer | 2.3yrs | US$2.67m | 0.12% $ 1.5m | |
| Corporate Controller & Principal Accounting Officer | 5.1yrs | sin datos | 0.029% $ 351.7k | |
| Vice President of Technical Operations | 3.3yrs | sin datos | sin datos | |
| Vice President of Strategic Finance & Investor Relations | no data | sin datos | sin datos | |
| Head of Corporate Communications & Media Relations | 2.3yrs | sin datos | sin datos | |
| Vice President of Sales & Sales Excellence | 2.7yrs | sin datos | sin datos | |
| VP & Head of Clinical Development | 1.7yrs | sin datos | sin datos | |
| Basel Site Head & Apraglutide Lifecycle Leader | 1.3yrs | sin datos | sin datos |
2.7yrs
Permanencia media
46yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de IRWD se considera experimentado (2.7 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | US$7.58m | 0.36% $ 4.5m | |
| Independent Director | 3.4yrs | US$300.71k | 0.064% $ 792.4k | |
| Member of Pharmaceuticals Advisory Committee | no data | sin datos | sin datos | |
| Independent Director | 3.5yrs | US$300.69k | 0.077% $ 945.0k | |
| Independent Director | 5.1yrs | US$300.71k | 0.34% $ 4.2m | |
| Independent Director | 8.1yrs | US$310.71k | 0.11% $ 1.3m | |
| Member of Pharmaceutical Advisory Committee | 7.3yrs | sin datos | sin datos | |
| Independent Director | 5.1yrs | US$310.69k | 0.081% $ 996.9k | |
| Independent Chairman of the Board | 10.3yrs | US$335.71k | 0.10% $ 1.3m | |
| Independent Director | 5.1yrs | US$300.71k | 0.061% $ 748.4k | |
| Independent Director | 5.1yrs | US$305.71k | 0.076% $ 938.0k |
5.1yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de IRWD se considera experimentada (5 años de antigüedad promedio).